Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Pharmaceutical industry --- Drug development. --- Quality control. --- Drug Development. --- Efficiency, Organizational. --- Total Quality Management. --- Development of drugs --- Drugs --- New drug development --- Pharmacology --- Pharmacy --- Development --- Lean Six Sigma --- Sigma Metrics --- Six Sigma --- Continuous Quality Management --- Lean Six Sigmas --- Management, Continuous Quality --- Management, Total Quality --- Metric, Sigma --- Metrics, Sigma --- Sigma Metric --- Sigma, Six --- Sigmas, Six --- Six Sigma, Lean --- Six Sigmas --- Six Sigmas, Lean --- Quality Control --- Administrative Efficiency --- Organizational Productivity --- Efficiency, Administrative --- Productivity, Organizational --- Program Efficiency --- Efficiency, Program --- Organizational Efficiency --- Program Efficiencies --- Medication Development --- Pharmaceutical Development --- Computational Prediction of Drug-Target Interactions --- Drug Target Prediction --- Development, Drug --- Development, Medication --- Development, Pharmaceutical --- Drug Target Predictions --- Prediction, Drug Target --- Target Prediction, Drug

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

"The development of a robust drug product requires juggling many competing priorities such as overcoming scientific challenges, following regulatory requirements, and managing business-related concerns. Unfortunately, despite large resources spent on R&D, multifactor productivity of pharmaceuticals is on the decline for several years now. Because of this business reality, pharmaceutical companies have seen a notable change in the traditional operating model and footprint over the past couple of decades. Outsourcing, in particular, has emerged as a successful business model for many pharmaceutical companies looking for ways to strategically increase their R&D capabilities and to augment their in-house resources. How to Integrate Quality by Efficient Design (QbED) in Product Development bridges the gap between theory and practice when it comes to strategic decision-making in a pharmaceutical research scenario. This book will introduce the concept of QbED and focus on various aspects such as patient-centric product designs, platform-based manufacturing technologies, business acuity, and regulatory strategies to balance the challenges in outsourcing with the need for strategic and statistically sound experiments rooted in good science. Detailed discussions will cover pharmaceutical business models, regulatory approval process, quality by design (QbD), business analytics, and manufacturing excellence specifically for small molecules and solid oral dosage forms. With the addition of case studies, flowcharts, diagrams, and data visualizations, How to Integrate Quality by Efficient Design (QbED) in Product Development will be a practical reference to help professionals working in the area of pharmaceutical drug development, strategy, and outsourcing management"--

Ethics and addiction --- Pharmaceutical industry --- Drug development. --- Drug Development. --- Efficiency, Organizational. --- Total Quality Management. --- Quality control. --- Lean Six Sigma --- Sigma Metrics --- Six Sigma --- Continuous Quality Management --- Lean Six Sigmas --- Management, Continuous Quality --- Management, Total Quality --- Metric, Sigma --- Metrics, Sigma --- Sigma Metric --- Sigma, Six --- Sigmas, Six --- Six Sigma, Lean --- Six Sigmas --- Six Sigmas, Lean --- Quality Control --- Administrative Efficiency --- Organizational Productivity --- Efficiency, Administrative --- Productivity, Organizational --- Program Efficiency --- Efficiency, Program --- Organizational Efficiency --- Program Efficiencies --- Medication Development --- Pharmaceutical Development --- Computational Prediction of Drug-Target Interactions --- Drug Target Prediction --- Development, Drug --- Development, Medication --- Development, Pharmaceutical --- Drug Target Predictions --- Prediction, Drug Target --- Target Prediction, Drug --- Development of drugs --- Drugs --- New drug development --- Pharmacology --- Pharmacy --- Development

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

drug discovery --- drug delivery --- medicinal chemistry --- drug development and commercialization --- translational science --- cell therapy --- Pharmacy --- Drug development --- Drugs --- Drug development. --- Drug Discovery. --- Drug Development. --- Research --- Design --- Testing --- Design. --- Testing. --- Research. --- Medication Development --- Pharmaceutical Development --- Computational Prediction of Drug-Target Interactions --- Drug Target Prediction --- Development, Drug --- Development, Medication --- Development, Pharmaceutical --- Drug Target Predictions --- Prediction, Drug Target --- Target Prediction, Drug --- Drug Prospecting --- Discovery, Drug --- Prospecting, Drug --- High-Throughput Screening Assays --- Bioprospecting --- Clinical drug trials --- Clinical trials of drugs --- Drug bioscreening --- Drug trials --- Clinical pharmacology --- Drug design --- Pharmaceutical design --- Development of drugs --- New drug development --- Pharmacology --- Medicaments --- Medications --- Medicine (Drugs) --- Medicines (Drugs) --- Pharmaceuticals --- Prescription drugs --- Bioactive compounds --- Medical supplies --- Pharmacopoeias --- Chemotherapy --- Materia medica --- Chemistry --- Medicine --- Clinical trials --- Effectiveness --- Evaluation --- Development --- Drug Discovery --- Drug Development

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Drug Development. --- Pharmacological and Toxicological Phenomena. --- Nervous System --- Hormones. --- drug effects. --- Hormone --- Hormone Receptor Agonists --- Agonists, Hormone Receptor --- Receptor Agonists, Hormone --- Endocrine Glands --- Pharmacologic and Toxicologic Phenomena --- Pharmacological and Toxicological Concepts --- Pharmacological and Toxicological Processes --- Pharmacotoxicologic Phenomena --- Pharmacotoxicologic Phenomenon --- Pharmacotoxicological Phenomena --- Pharmacotoxicological Phenomenon --- Toxicopharmacological Phenomena --- Toxicopharmacological Phenomenon --- Phenomena, Pharmacotoxicologic --- Phenomena, Pharmacotoxicological --- Phenomena, Toxicopharmacological --- Phenomenon, Pharmacotoxicologic --- Phenomenon, Pharmacotoxicological --- Phenomenon, Toxicopharmacological --- Pharmacologic Actions --- Medication Development --- Pharmaceutical Development --- Computational Prediction of Drug-Target Interactions --- Drug Target Prediction --- Development, Drug --- Development, Medication --- Development, Pharmaceutical --- Drug Target Predictions --- Prediction, Drug Target --- Target Prediction, Drug --- Nervous system. --- Neuropharmacology.. --- Pharmacology. --- Drug effects --- Medical pharmacology --- Medical sciences --- Chemicals --- Chemotherapy --- Drugs --- Pharmacy --- Nervous system --- Neurotropic drugs --- Neurosciences --- Pharmacology --- Organs (Anatomy) --- Physiological effect --- Effect of drugs on

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Drug–drug interactions (DDIs) cause a drug to affect other drugs, leading to reduced drug efficacy or increased toxicity of the affected drug. Some well-known interactions are known to be the cause of adverse drug reactions (ADRs) that are life threatening to the patient. Traditionally, DDI have been evaluated around the selective action of drugs on specific CYP enzymes. The interaction of drugs with CYP remains very important in drug interactions but, recently, other important mechanisms have also been studied as contributing to drug interaction including transport- or UDP-glucuronyltransferase as a Phase II reaction-mediated DDI. In addition, novel mechanisms of regulating DDIs can also be suggested. In the case of the substance targeted for interaction, not only the DDIs but also the herb–drug or food–drug interactions have been reported to be clinically relevant in terms of adverse side effects. Reporting examples of drug interactions on a marketed drug or studies on new mechanisms will be very helpful for preventing the side effects of the patient taking these drugs. This Special Issue aims to highlight current progress in understanding both the clinical and nonclinical interactions of commercial drugs and the elucidation of the mechanisms of drug interactions.

Research & information: general --- Biology, life sciences --- tadalafil --- ticagrelor --- drug-drug interaction --- pharmacokinetics --- plasma concentration --- CYP3A4 --- Loxoprofen --- CYP3A --- Dexamethasone --- Ketoconazole --- CYP2D6 --- O-desmethyltramadol --- physiologically-based pharmacokinetics --- tramadol --- (‒)-sophoranone --- CYP2C9 --- potent inhibition --- in vitro --- in vivo --- drug interaction --- low permeability --- high plasma protein binding --- biflavonoid --- cytochrome P450 --- drug interactions --- selamariscina A --- uridine 5′-diphosphoglucuronosyl transferase --- tissue-specific --- systemic exposure --- P-glycoprotein (P-gp) --- organic anion transporting polypeptide 1A2 (OATP1A2) --- Rumex acetosa --- fexofenadine --- chronic kidney disease --- drug–drug interactions --- polypharmacy --- adverse drug reactions --- Lexicomp --- subset analysis --- signal detection algorithms --- spontaneous reporting systems --- mechanism-based inhibition --- competitive inhibition --- non-competitive inhibition --- substrate --- inhibitor --- cytochromes P450 --- OATP1B1 --- OATP1B3 --- tyrosine kinase inhibitors --- drug-drug interactions --- migraine --- lasmiditan --- gepants --- monoclonal antibodies --- CYP1A1 --- CYP1A2 --- drug–drug interaction --- expression --- metabolism --- regulation --- drug transporter --- ubiquitination --- ixazomib --- DDI --- computational prediction --- in silico --- QSAR --- drug metabolism --- ADME --- CYP --- metabolic DDI --- P450 --- 1A2 --- 2B6 --- 2C19 --- 2C8 --- 2C9 --- 2D6 --- 3A4